Compare Citius Pharmaceuticals Inc (CTXR) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lockheed Martin Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Lockheed Martin Corporation trades at $517.1 (market cap $118.74B). The key difference: Lockheed Martin Corporation is far larger — about 8110.7× Citius Pharmaceuticals Inc's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LMT | |
|---|---|---|
Market Cap | $14.64M | $118.74B |
Sector | Health | Industrials |
52-Week High | $1.82 | $676.70 |
52-Week Low | $0.53 | $410.74 |
Enterprise Value | $10.86M | $137.54B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Lockheed Martin (LMT) trades at $520.68, down 0.49% on the day, with a bearish technical signal and mixed earnings history. The company reported $75.05B in 2025 revenue and a net income margin of 6.38%, while maintaining a $194B backlog as of Q4 2025 (24/7 Wall Street, 2026-07-13). Analyst consensus is bullish with a $614 price target, supported by strong defense spending trends.
Outlook remains positive due to robust demand from global defense budgets, but risks include execution challenges and margin pressure. The stock offers value with a P/E of 25.21 and dividend yield near 2.66%, though recent EPS misses warrant caution. Institutional sentiment favors long-term growth amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
